Fab I inhibitors

US6503903B1 · kind B1 · utility

Assignee

• SmithKline Beecham Limited · US

Inventors

• William Henry Miller · Collegeville, US
• Kenneth A. Newlander · West Chester, US
• Mark A. Seefeld · Collegeville, US

Key dates

• Filing date: Oct 18, 2001
• Grant date: Jan 7, 2003
• Expiry date: Oct 18, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment bacterial infections: wherein:R1 is H, C1-6alkyl or Ar—C0-6alkyl;R2 is H, C1-6alkyl, Ar—C0-6alkyl, HO—(CH2)n— or R′OC(O)—(CH2)n—;R3 is A—C0-4alkyl, A—C2-4alkenyl, A—C2-4alkynyl, A—C3-4oxoalkenyl, A—C3-4oxoalkynyl, A—C1-4aminoalkyl, A—C3-4aminoalkenyl, A—C3-4aminoalkynyl, optionally substituted by any accessible combination of one or more of R10 or R7; R5 is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl;A is H, C3-6cycloalkyl, Het or Ar;R7 is —COR8, —COCR′2R9, —C(S)R8, —S(O)kOR′, —S(O)kNR′R″, —PO(OR′), —PO(OR′)2, —B(OR′)2, —NO2, or tetrazolyl;R8 is —OR′, —NR′R″, —NR′SO2R′, —NR′OR′, or —OCR′2CO(O)R′;R9 is —OR′, —CN, —S(O)rR′, —S(O)kNR′2, —C(O)R′, C(O)NR′2, or —CO2R′;R10 is H, halo, —OR11, —CN, —NR′R11, —N…